| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to drugs and concerns a pharmaceutical combination containing the effective amounts of: (i) a compounds n , where L n ·R 5 m , R 1 , R 2 , R 3 and R 4 have values specified in the formula and (ii) at least one additional therapeutic agent 2 chosen from a group consisting of nucleoside biphosphate reductase inhibitors chosen from cytarabine and pemetrexed, histone deacetylase inhibitors, irinotecan, docetaxel, cisplatin, taxotere, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-butene-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline or its pharmaceutically acceptable salt and 3-Z-[1-(4-(N-((4-methylpiperazine-1-yl)-methylcarbonyl)-N-methylamino)-anilino)-1-phenylmethylene]-6-methoxycarbonyl-2-indolinone for oncotherapy. n EFFECT: combination under the invention shows a synergetic effect in oncotherapy. n 18 cl, 8 dwg, 1 tbl, 25 ex |